These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21554161)

  • 21. Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: comparison with lactose carrier.
    Hassan MS; Lau R
    Int J Pharm; 2010 Feb; 386(1-2):6-14. PubMed ID: 19922775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN; Bierend H; Robins E; Steckel H; Flament MP
    Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro.
    Srichana T; Martin GP; Marriott C
    Eur J Pharm Sci; 1998 Dec; 7(1):73-80. PubMed ID: 9845780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurement of electrostatic charge decay in pharmaceutical powders and polymer materials used in dry powder inhaler devices.
    Carter PA; Rowley G; Fletcher EJ; Stylianopoulos V
    Drug Dev Ind Pharm; 1998 Nov; 24(11):1083-8. PubMed ID: 9876564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics.
    Hickey AJ; Mansour HM; Telko MJ; Xu Z; Smyth HD; Mulder T; McLean R; Langridge J; Papadopoulos D
    J Pharm Sci; 2007 May; 96(5):1302-19. PubMed ID: 17455364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions.
    Bhavna ; Ahmad FJ; Mittal G; Jain GK; Malhotra G; Khar RK; Bhatnagar A
    Eur J Pharm Biopharm; 2009 Feb; 71(2):282-91. PubMed ID: 18984050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient.
    Kaialy W; Martin GP; Ticehurst MD; Momin MN; Nokhodchi A
    Int J Pharm; 2010 Jun; 392(1-2):178-88. PubMed ID: 20363301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aerosolization behavior of carrier-free L-leucine coated salbutamol sulphate powders.
    Raula J; Lähde A; Kauppinen EI
    Int J Pharm; 2009 Jan; 365(1-2):18-25. PubMed ID: 18789380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design.
    Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G
    Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of realistic inspiratory flow profiles on fine particle fractions of dry powder aerosol formulations.
    Martin GP; Marriott C; Zeng XM
    Pharm Res; 2007 Feb; 24(2):361-9. PubMed ID: 17177114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of storage humidity on the in vitro inhalation properties of salbutamol sulfate dry powder with surface covered lactose carrier.
    Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenberger H
    Chem Pharm Bull (Tokyo); 2004 Apr; 52(4):444-6. PubMed ID: 15056961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers.
    Corrigan DO; Corrigan OI; Healy AM
    Int J Pharm; 2006 Sep; 322(1-2):22-30. PubMed ID: 16815654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate.
    Tee SK; Marriott C; Zeng XM; Martin GP
    Int J Pharm; 2000 Nov; 208(1-2):111-23. PubMed ID: 11064216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immobilization of fine particles on lactose carrier by precision coating and its effect on the performance of dry powder formulations.
    Chan LW; Lim LT; Heng PW
    J Pharm Sci; 2003 May; 92(5):975-84. PubMed ID: 12712417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of surface layering time of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
    Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenberger H
    Chem Pharm Bull (Tokyo); 2004 Mar; 52(3):350-3. PubMed ID: 14993760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of carrier particle shape on dry powder inhaler performance.
    Kaialy W; Alhalaweh A; Velaga SP; Nokhodchi A
    Int J Pharm; 2011 Dec; 421(1):12-23. PubMed ID: 21945739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surface modification of lactose inhalation blends by moisture.
    Watling CP; Elliott JA; Scruton C; Cameron RE
    Int J Pharm; 2010 May; 391(1-2):29-37. PubMed ID: 20156536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation.
    Chiou H; Li L; Hu T; Chan HK; Chen JF; Yun J
    Int J Pharm; 2007 Feb; 331(1):93-8. PubMed ID: 17052870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of drug loading on formulation structure and aerosol performance in carrier based dry powder inhalers.
    Young PM; Wood O; Ooi J; Traini D
    Int J Pharm; 2011 Sep; 416(1):129-35. PubMed ID: 21708238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate.
    Larhrib H; Zeng XM; Martin GP; Marriott C; Pritchard J
    Int J Pharm; 1999 Nov; 191(1):1-14. PubMed ID: 10556735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.